PT 141

So What Does This Actually Mean?

Plain English summary — no PhD required

PT-141 (Bremelanotide) is a synthetic peptide that works through the brain's melanocortin system to influence sexual arousal. Unlike drugs like Viagra or Cialis, which work by increasing blood flow to genital tissue, PT-141 works centrally — in the brain — activating the neural pathways that generate sexual desire itself. It was FDA-approved in 2019 under the brand name Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women.

What It Does

PT-141 activates melanocortin receptors (primarily MC3R and MC4R) in the hypothalamus and limbic system — brain regions that regulate motivation, reward, and sexual behavior. This central mechanism produces arousal at the neurological level rather than just the vascular level. In the FDA approval trials, Vyleesi® demonstrated statistically significant improvements in sexual desire and reductions in distress related to low desire compared to placebo.

Why It Matters

The distinction between a central (brain-based) and peripheral (blood flow-based) mechanism for sexual function is clinically significant. Many cases of sexual dysfunction, particularly in women, involve desire and arousal at the psychological/neurological level rather than purely vascular issues. PT-141's FDA approval for HSDD validates the melanocortin pathway as a legitimate therapeutic target for sexual health.

The Bottom Line

PT-141 is FDA-approved as Vyleesi® for female sexual desire disorder, giving it one of the strongest clinical validation profiles in this catalog. Its central mechanism — working through the brain rather than blood vessels — distinguishes it from conventional sexual health drugs. The research-grade peptide supplied by Purgo Labs is for laboratory use only.

Overview

What is PT-141?

PT-141, clinically known as bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It is FDA-approved under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides in this catalog with full regulatory approval and extensive human clinical data.

Unlike phosphodiesterase-5 (PDE5) inhibitors such as sildenafil, which act peripherally on vascular smooth muscle, PT-141 acts centrally through melanocortin receptors in the brain — specifically MC3R and MC4R in the hypothalamus and limbic system. This central mechanism of action represents a fundamentally different approach to sexual dysfunction research.

Key Takeaways

• PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist — the same compound FDA-approved as Vyleesi® (2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women.

• Activates MC3R and MC4R in the central nervous system, particularly in the hypothalamus and limbic system, producing pro-sexual effects through a CNS pathway distinct from PDE5 inhibitors (sildenafil, tadalafil).

• Unlike PDE5 inhibitors which act peripherally on vascular smooth muscle, PT-141 acts centrally — it can produce sexual arousal in the absence of direct genital stimulation, and works in both men and women.

• The FDA approval of bremelanotide (Vyleesi®) provides robust clinical validation: Phase 3 trials showed statistically significant improvements in desire and reductions in distress in women with HSDD.

• Research applications include studying the central melanocortin system's role in sexual motivation, the MC4R pathway in reward and arousal, and potential applications in male sexual dysfunction.

Composition

Molecular Composition

Amino Acid Sequence

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

PT-141 (bremelanotide) has the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, differing from Melanotan II (MT2) by a single modification: the C-terminal amide group of MT2 is replaced by a free carboxylic acid (OH) in PT-141. This modification reduces the compound's melanogenic activity (reducing tanning side effects) while preserving its central melanocortin receptor agonism.

The molecular weight is 1,025.2 Daltons. The cyclic structure, formed by a lactam bridge between aspartate and lysine, confers metabolic stability and enhanced receptor binding affinity.

Mechanism of Action

How Does It Work?

!

PT-141 increases sexual desire by activating melanocortin receptors in the hypothalamus, enhancing dopaminergic signaling in the brain's reward and arousal circuits.

PT-141 exerts its primary effects through agonism at MC3R and MC4R in the central nervous system, particularly in the hypothalamus, limbic system, and spinal cord. MC4R activation in the medial preoptic area (MPOA) of the hypothalamus — a region critical for sexual motivation and behavior — increases dopaminergic neurotransmission in the mesolimbic pathway, enhancing sexual desire and arousal.

Unlike PDE5 inhibitors, which require sexual stimulation to be effective and act primarily on penile/clitoral blood flow, PT-141 modulates the central neural circuits that generate sexual desire. This distinction is clinically significant: PT-141 can increase sexual motivation in the absence of external stimulation, addressing the desire component of sexual dysfunction rather than the performance component.